Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease ... and improving the quality of life for patients. Medications such as riluzole and edaravone have been approved to help slow ...

Living in a disadvantaged community may decrease the length of time a person can survive with amyotrophic lateral sclerosis, or ALS, by over 30%, a study suggests. Similar studies have shown that ...

A team of researchers from the Sant Pau Research Institute (IR Sant Pau) has published a study in the Journal of ...

Discover the latest developments in potential ALS treatments with COYA-302 and COYA-303, set to impact the $1.33 billion ...

Trouble sleeping is common in other neurodegenerative diseases, but past research has only suggested that it occurs in patients with amyotrophic lateral sclerosis. | Trouble sleeping is common in ...

A retrospective analysis showed IV edaravone in participants with ALS was associated with fewer reported disease progression milestones and deaths than control.

While the continued erosion of Biogen’s multiple sclerosis franchise and weaker-than-expected 2025 guidance doesn’t seem to ...

Living in a disadvantaged community may decrease the length of time a person can survive with amyotrophic lateral sclerosis, or ALS, by over 30%, a Michigan Medicine-led study suggests.

A new UCLA Health study has discovered in mouse models that genes associated with repairing mismatched DNA are critical in eliciting damages to neurons that are most vulnerable in Huntington's disease ...

Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal ...

Ziwig, a French biotech company committed to advancing women's health, announces the fast-track reimbursement of Ziwig ...

Barbara Goodfriend, 83, opted for medical aid in dying after being diagnosed with ALS. The New Jersey widow ended her life in ...